These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 20720259)

  • 1. Oral administration of glucagon-like peptide 1 or peptide YY 3-36 affects food intake in healthy male subjects.
    Steinert RE; Poller B; Castelli MC; Drewe J; Beglinger C
    Am J Clin Nutr; 2010 Oct; 92(4):810-7. PubMed ID: 20720259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of PYY3-36 and GLP-1 on energy intake, energy expenditure, and appetite in overweight men.
    Schmidt JB; Gregersen NT; Pedersen SD; Arentoft JL; Ritz C; Schwartz TW; Holst JJ; Astrup A; Sjödin A
    Am J Physiol Endocrinol Metab; 2014 Jun; 306(11):E1248-56. PubMed ID: 24735885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of glucagon-like peptide-1 receptor antagonism on appetite and food intake in healthy men.
    Steinert RE; Schirra J; Meyer-Gerspach AC; Kienle P; Fischer H; Schulte F; Goeke B; Beglinger C
    Am J Clin Nutr; 2014 Aug; 100(2):514-23. PubMed ID: 24965303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively.
    Neary NM; Small CJ; Druce MR; Park AJ; Ellis SM; Semjonous NM; Dakin CL; Filipsson K; Wang F; Kent AS; Frost GS; Ghatei MA; Bloom SR
    Endocrinology; 2005 Dec; 146(12):5120-7. PubMed ID: 16150917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptide YY and glucagon-like peptide-1 contribute to decreased food intake after Roux-en-Y gastric bypass surgery.
    Svane MS; Jørgensen NB; Bojsen-Møller KN; Dirksen C; Nielsen S; Kristiansen VB; Toräng S; Wewer Albrechtsen NJ; Rehfeld JF; Hartmann B; Madsbad S; Holst JJ
    Int J Obes (Lond); 2016 Nov; 40(11):1699-1706. PubMed ID: 27434221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.
    Näslund E; Barkeling B; King N; Gutniak M; Blundell JE; Holst JJ; Rössner S; Hellström PM
    Int J Obes Relat Metab Disord; 1999 Mar; 23(3):304-11. PubMed ID: 10193877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Orally administered glucagon-like peptide-1 affects glucose homeostasis following an oral glucose tolerance test in healthy male subjects.
    Steinert RE; Poller B; Castelli MC; Friedman K; Huber AR; Drewe J; Beglinger C
    Clin Pharmacol Ther; 2009 Dec; 86(6):644-50. PubMed ID: 19727071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamic effects of oral GLP-1 and PYY3-36: a proof-of-concept study in healthy subjects.
    Beglinger C; Poller B; Arbit E; Ganzoni C; Gass S; Gomez-Orellana I; Drewe J
    Clin Pharmacol Ther; 2008 Oct; 84(4):468-74. PubMed ID: 19238651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small intestinal protein infusion in humans: evidence for a location-specific gradient in intestinal feedback on food intake and GI peptide release.
    van Avesaat M; Ripken D; Hendriks HF; Masclee AA; Troost FJ
    Int J Obes (Lond); 2017 Feb; 41(2):217-224. PubMed ID: 27811949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intraduodenal infusion of a combination of tastants decreases food intake in humans.
    van Avesaat M; Troost FJ; Ripken D; Peters J; Hendriks HF; Masclee AA
    Am J Clin Nutr; 2015 Oct; 102(4):729-35. PubMed ID: 26289437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Irregular meal-pattern effects on energy expenditure, metabolism, and appetite regulation: a randomized controlled trial in healthy normal-weight women.
    Alhussain MH; Macdonald IA; Taylor MA
    Am J Clin Nutr; 2016 Jul; 104(1):21-32. PubMed ID: 27305952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of dipeptidyl peptidase IV inhibition on glycemic, gut hormone, triglyceride, energy expenditure, and energy intake responses to fat in healthy males.
    Heruc GA; Horowitz M; Deacon CF; Feinle-Bisset C; Rayner CK; Luscombe-Marsh N; Little TJ
    Am J Physiol Endocrinol Metab; 2014 Nov; 307(9):E830-7. PubMed ID: 25231186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men.
    Näslund E; Gutniak M; Skogar S; Rössner S; Hellström PM
    Am J Clin Nutr; 1998 Sep; 68(3):525-30. PubMed ID: 9734726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics.
    Lee A; Patrick P; Wishart J; Horowitz M; Morley JE
    Diabetes Obes Metab; 2002 Sep; 4(5):329-35. PubMed ID: 12190996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PYY3-36 and oxyntomodulin can be additive in their effect on food intake in overweight and obese humans.
    Field BC; Wren AM; Peters V; Baynes KC; Martin NM; Patterson M; Alsaraf S; Amber V; Wynne K; Ghatei MA; Bloom SR
    Diabetes; 2010 Jul; 59(7):1635-9. PubMed ID: 20357366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exogenous peptide YY3-36 and Exendin-4 further decrease food intake, whereas octreotide increases food intake in rats after Roux-en-Y gastric bypass.
    Fenske WK; Bueter M; Miras AD; Ghatei MA; Bloom SR; le Roux CW
    Int J Obes (Lond); 2012 Mar; 36(3):379-84. PubMed ID: 21694700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initial evidence that GLP-1 receptor blockade fails to suppress postprandial satiety or promote food intake in humans.
    Melhorn SJ; Tyagi V; Smeraglio A; Roth CL; Schur EA
    Appetite; 2014 Nov; 82():85-90. PubMed ID: 25049134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of peptide YY3-36 on food intake in humans.
    Degen L; Oesch S; Casanova M; Graf S; Ketterer S; Drewe J; Beglinger C
    Gastroenterology; 2005 Nov; 129(5):1430-6. PubMed ID: 16285944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peptide YY3-36 and glucagon-like peptide-1 in functional dyspepsia. Secretion and role in symptom generation.
    Witte AB; Hilsted L; Holst JJ; Schmidt PT
    Scand J Gastroenterol; 2016; 51(4):400-9. PubMed ID: 26503455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2.
    Gutzwiller JP; Drewe J; Göke B; Schmidt H; Rohrer B; Lareida J; Beglinger C
    Am J Physiol; 1999 May; 276(5):R1541-4. PubMed ID: 10233049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.